Antonia, S.Villegas, A.Daniel, D.Vicente, D.Murakami, S.Hui, R.Kurata, T.Chiappori, A.Lee, K. H.De Wit, M.Cho, B. C.Bourhaba, M.Quantin, X.Tokito, T.Mekhail, T.Planchard, D.Kim, Y.Karapetis, C.Hiret, S.Ostoros, G.Kubota, K.Gray, J.Paz-Ares, L.Carpeno, J. De CastroFaivre-Finn, C.Reck, M.Vansteenkiste, J.Spigel, D.Wadsworth, C.Taboada, M.Dennis, P.Ozguroglu, M.2025-01-072025-01-072018-10-011556-0864https://hdl.handle.net/10668/27560enNSCLCdurvalumabPACIFICOverall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFICconference outputopen access10.1016/j.jtho.2018.08.0101556-1380http://www.jto.org/article/S1556086418309687/pdf454014500002